Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment

Simão-Gurge, Raquel Maria; Costa‐Carvalho, Beatriz Tavares; Nobre, Fernanda Aimée; Gonzalez, Isabela G. S.; Moraes-Pinto, Maria Isabel de

doi:10.1016/j.aller.2016.04.014

Cited by 6 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests that the initial concentration of specific antibodies in an IgG preparation determines the antibody levels achieved in vivo. Interestingly, circulating antibody levels were very similar to antibody concentrations achieved with weekly subcutaneous infusions …”

Section: Pneumococcal Immunity In Human Gamma Globulinsupporting

confidence: 59%

“…Interestingly, circulating antibody levels were very similar to antibody concentrations achieved with weekly subcutaneous infusions. 39,40 Tuerlinckx et al 41 observed that distribution curves differed between serotypes and showed wide dispersion among patients. In 89% to 100% of patients, antibodies against most serotypes reached trough levels of 0.2 μg/mL, a threshold they considered protective against invasive pneumococcal infection.…”

Section: Pneumococcal Immunity In Human Gamma Globulinmentioning

confidence: 99%

See 1 more Smart Citation

Overview of antibody‐mediated immunity to S. pneumoniae: pneumococcal infections, pneumococcal immunity assessment, and recommendations for IG product evaluation

Sorensen

Edgar

2018

Transfusion

View full text Add to dashboard Cite

Streptococcus pneumoniae (S. pneumoniae) strains colonize the nasopharynx and can cause mucosal infections in the upper airway and middle ear, pneumonias, and invasive infections like bacteremia, sepsis, and meningitis. Over 90 serotypes, defined by the structure of their capsular polysaccharides, are known. Twenty‐three of these serotypes cause most infections and several of these serotypes can develop antibiotic resistance. Susceptibility factors that increase the susceptibility to S. pneumoniae mucosal and invasive infections include all forms of primary and secondary antibody deficiencies. Many patients affected by one of these deficiencies benefit from the regular administration of human gamma globulin (IgG) preparations. Donors of plasma units used to prepare human IgG have varying concentrations of IgG antibodies against relevant S. pneumoniae serotypes. These antibodies are developed in response to colonization and common subclinical infections and by routine vaccination with S. pneumoniae polysaccharide vaccines. The presence of an adequate concentration of these protective antibodies against all prevalent serotypes needs to be determined to assure the effectiveness of human IgG. All presently available methods to assess IgG antibodies against S. pneumoniae capsular polysaccharides have advantages and pitfalls that are analyzed in this review. In vitro testing does not provide a complete or necessarily accurate measurement of the effectiveness of antibodies in vivo. For regulatory purposes, caution needs to be used in the interpretation of currently available assays that measure pneumococcal antibody levels. Monitoring S. pneumoniae infections in patients treated with IgG and tracing information about IgG lots used to treat these patients should be encouraged.

show abstract

Section: Pneumococcal Immunity In Human Gamma Globulinsupporting

confidence: 59%

Section: Pneumococcal Immunity In Human Gamma Globulinmentioning

confidence: 99%

Overview of antibody‐mediated immunity to S. pneumoniae: pneumococcal infections, pneumococcal immunity assessment, and recommendations for IG product evaluation

Sorensen

Edgar

2018

Transfusion

View full text Add to dashboard Cite

show abstract

“…B cell deficiency has often been associated with the impairment of immunity against infection. Individuals with X-linked agammaglobulinemia (XLA) have a mutation in the gene that is responsible for Bruton tyrosine kinase (BTK), which involves a failure in antibody production and a high susceptibility to bacterial infections (Simao-Gurge et al, 2017). There is a murine model that exhibits the same impairment and leads to a similar state of susceptibility to that in humans.…”

Section: Introductionmentioning

confidence: 99%

B-1 Cells May Drive Macrophages Susceptibility to Trypanosoma cruzi Infection

et al. 2019

View full text Add to dashboard Cite

B-1 cells can directly and indirectly influence the immune response. These cells are known to be excellent producers of natural antibodies and can secrete a variety of immunomodulatory molecules. They are also able to differentiate into B-1 cell-derived phagocytes (B-1CDP). B-1 cells can modulate macrophages to become less effective, and B-1CDP cells are more susceptible in infection models. In this work, we investigated the microbicidal ability of these cells in Trypanosoma cruzi infection in vitro. The results show that macrophages from BALB/c mice are more susceptible to infection than macrophages from XID mice. The resistance observed in macrophages from XID mice was abolished in the presence of B-1 cells, and this event seems to be associated with IL-10 production by B-1 cells, which may have contributed to the decrease of NO production. Additionally, B-1CDP cells were more permissive to intracellular T. cruzi infection than peritoneal macrophages. These findings strongly suggest that B-1 cells and B-1CDP cells have a potential role in the persistence of the parasite in host cells.

show abstract

“…In 2017, Simão‐Gurge et al measured total IgG levels as well as pneumococcal IgG for six serotypes via WHO ELISA in trough serum samples from 21 pediatric and adult patients receiving IVIG. These levels were compared to total IgG and pneumococcal IgG levels from the IVIG preparations that were administered to the participants.…”

Section: Pneumococcal Antibodies In Immunoglobulin Productsmentioning

confidence: 99%

Measuring quantity and function of pneumococcal antibodies in immunoglobulin products

LaFon

Nahm

2018

Transfusion

View full text Add to dashboard Cite

BACKGROUND Immunoglobulin replacement therapy is a cornerstone of the treatment of primary immunodeficiencies. Preparations used for replacement therapy are processed by purifying immunoglobulins from large pools of plasma, which were obtained from healthy donors. The constituent antibodies in these products depend on the immune history of the donor pool as well as manufacturing processes that differ among manufacturers. For these reasons various methods have been proposed to examine the levels and function of antibodies to organisms such as Streptococcus pneumoniae, which frequently causes infections in patients with immunodeficiencies. Pneumococcal antibody levels or antibody function can be measured with enzyme‐linked immunosorbent assay (ELISA) or multiplexed opsonophagocytosis assay (MOPA). Although these assays were developed initially to assess the immunogenicity of pneumococcal vaccines, the techniques have been adapted to evaluate immunoglobulin products as well. STUDY DESIGN AND METHODS This article provides a concise review of the analytic techniques for measuring pneumococcal antibodies and prior studies of immunoglobulin products utilizing these methods. RESULTS Studies utilizing these assays have demonstrated that antibody levels of immunoglobulin products can vary with time, location, and manufacturer. CONCLUSIONS We highlight current issues and future considerations concerning measurement of pneumococcal antibodies in immunoglobulin products, and the assays used for this purpose.

show abstract

Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment

Abstract: Pneumococcal antibodies are present in a high range of concentrations in sera from PID patients and also in IVIG preparations. Even maintaining a recommended IgG trough level, these patients can be susceptible to these bacteria and that may contribute to recurrent respiratory infections.

Cited by 6 publications

References 24 publications

Overview of antibody‐mediated immunity to S. pneumoniae: pneumococcal infections, pneumococcal immunity assessment, and recommendations for IG product evaluation

Overview of antibody‐mediated immunity to S. pneumoniae: pneumococcal infections, pneumococcal immunity assessment, and recommendations for IG product evaluation

B-1 Cells May Drive Macrophages Susceptibility to Trypanosoma cruzi Infection

Measuring quantity and function of pneumococcal antibodies in immunoglobulin products

Contact Info

Product

Resources

About